Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
11/08/2026 12:46
BRIEF-Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights Aug 11 (Reuters) - Aura Biosciences, Inc. AURA.O:
AURA BIOSCIENCES REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
AURA BIOSCIENCES, - PHASE 3 COMPASS TRIAL FULLY ENROLLED WITH 108 PATIENTS; TOPLINE DATA EXPECTED IN 2H 2027
AURA BIOSCIENCES, - ORGANIZATIONAL RESTRUCTURING AND CAPITAL ALLOCATION EXTEND CASH RUNWAY INTO 1H 2029
AURA BIOSCIENCES, - REDUCES WORKFORCE BY ABOUT 20% TO FOCUS ON OCULAR ONCOLOGY
Source text: ID:nGNX9Zn89p
Further company coverage: AURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs